Anti-LPL Antibody, clone 2C5

Lipoprotein lipase (LPL) is encoded by the LPL/LIPD gene in humans and is a lipase that localizes to the plasma membrane of the microvilli of hepatocytes and the luminal surface of endothelial cells in capillaries. It is expressed in a wide variety of tissues from fat and heart to muscle and mammary glands. It can also be found in the blood bound to lipoproteins. Its function is to hydrolyze triglycerides from the blood and other sources into free fatty acids; LPL also acts as receptor and binding factor for lipoprotein uptake and allows for the catalysis of VLDL from the blood. Expression and regulation of LPL differ by tissue type, some factors such as insulin can stimulate LPL expression in fat tissues, where as insulin down regulates LPL expression on muscle. Recently because serum triglyceride levels are linked with the development of cancer, LPL has become a target for cancer prevention and therapy because LPL catalyzes plasma triglycerides leading to lower levels, it is thought that LPL assisted therapy could be useful in preventing or treating cancers. EMD-Millipore’s Anti-LPL mouse monoclonal antibody has been tested on western blots using HeLa cell lysates.

~53 kDa observed

Purified recombinant fragment of human LPL expressed in E. Coli.

Anti-LPL Antibody, clone 2C5 is a mouse monoclonal antibody & validated for use in western blotting.

Control
Hela cell lysate

Evaluated by Western Blotting in Hela cell lysate.

Western Blotting Analysis: A 1:500-2,000 dilution of this antibody detected LPL in Hela cell lysate.

Optimal working dilutions must be determined by end user.